1061 related articles for article (PubMed ID: 29414259)
1. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.
Hashimoto M; Kamphorst AO; Im SJ; Kissick HT; Pillai RN; Ramalingam SS; Araki K; Ahmed R
Annu Rev Med; 2018 Jan; 69():301-318. PubMed ID: 29414259
[TBL] [Abstract][Full Text] [Related]
2. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Im SJ; Hashimoto M; Gerner MY; Lee J; Kissick HT; Burger MC; Shan Q; Hale JS; Lee J; Nasti TH; Sharpe AH; Freeman GJ; Germain RN; Nakaya HI; Xue HH; Ahmed R
Nature; 2016 Sep; 537(7620):417-421. PubMed ID: 27501248
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade.
Jadhav RR; Im SJ; Hu B; Hashimoto M; Li P; Lin JX; Leonard WJ; Greenleaf WJ; Ahmed R; Goronzy JJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14113-14118. PubMed ID: 31227606
[TBL] [Abstract][Full Text] [Related]
4. Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
Mariniello A; Nasti TH; Chang DY; Hashimoto M; Malik S; McManus DT; Lee J; McGuire DJ; Cardenas MA; Umana P; Nicolini V; Antia R; Saha A; Buchwald Z; Kissick H; Ghorani E; Novello S; Sangiolo D; Scagliotti GV; Ramalingam SS; Ahmed R
Clin Cancer Res; 2024 May; 30(9):1833-1845. PubMed ID: 37992307
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.
Viramontes KM; Neubert EN; DeRogatis JM; Tinoco R
Front Immunol; 2022; 13():869768. PubMed ID: 35774790
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
7. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells.
Odorizzi PM; Pauken KE; Paley MA; Sharpe A; Wherry EJ
J Exp Med; 2015 Jun; 212(7):1125-37. PubMed ID: 26034050
[TBL] [Abstract][Full Text] [Related]
8. Exhaustion of the CD8
Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
Front Immunol; 2018; 9():446. PubMed ID: 29563914
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
10. Role of PD-1 during effector CD8 T cell differentiation.
Ahn E; Araki K; Hashimoto M; Li W; Riley JL; Cheung J; Sharpe AH; Freeman GJ; Irving BA; Ahmed R
Proc Natl Acad Sci U S A; 2018 May; 115(18):4749-4754. PubMed ID: 29654146
[TBL] [Abstract][Full Text] [Related]
11. CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy.
Ando S; Araki K
Int Immunol; 2022 Oct; 34(11):571-577. PubMed ID: 35901837
[TBL] [Abstract][Full Text] [Related]
12. Subsets of exhausted CD8
Miller BC; Sen DR; Al Abosy R; Bi K; Virkud YV; LaFleur MW; Yates KB; Lako A; Felt K; Naik GS; Manos M; Gjini E; Kuchroo JR; Ishizuka JJ; Collier JL; Griffin GK; Maleri S; Comstock DE; Weiss SA; Brown FD; Panda A; Zimmer MD; Manguso RT; Hodi FS; Rodig SJ; Sharpe AH; Haining WN
Nat Immunol; 2019 Mar; 20(3):326-336. PubMed ID: 30778252
[TBL] [Abstract][Full Text] [Related]
13. PD-1 combination therapy with IL-2 modifies CD8
Hashimoto M; Araki K; Cardenas MA; Li P; Jadhav RR; Kissick HT; Hudson WH; McGuire DJ; Obeng RC; Wieland A; Lee J; McManus DT; Ross JL; Im SJ; Lee J; Lin JX; Hu B; West EE; Scharer CD; Freeman GJ; Sharpe AH; Ramalingam SS; Pellerin A; Teichgräber V; Greenleaf WJ; Klein C; Goronzy JJ; Umaña P; Leonard WJ; Smith KA; Ahmed R
Nature; 2022 Oct; 610(7930):173-181. PubMed ID: 36171288
[TBL] [Abstract][Full Text] [Related]
14. Restoring function in exhausted CD8 T cells during chronic viral infection.
Barber DL; Wherry EJ; Masopust D; Zhu B; Allison JP; Sharpe AH; Freeman GJ; Ahmed R
Nature; 2006 Feb; 439(7077):682-7. PubMed ID: 16382236
[TBL] [Abstract][Full Text] [Related]
15. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade.
Blackburn SD; Shin H; Freeman GJ; Wherry EJ
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15016-21. PubMed ID: 18809920
[TBL] [Abstract][Full Text] [Related]
16. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.
Park HJ; Park JS; Jeong YH; Son J; Ban YH; Lee BH; Chen L; Chang J; Chung DH; Choi I; Ha SJ
J Immunol; 2015 Jun; 194(12):5801-11. PubMed ID: 25934860
[TBL] [Abstract][Full Text] [Related]
17. Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion.
Ahn E; Youngblood B; Lee J; Lee J; Sarkar S; Ahmed R
J Virol; 2016 Oct; 90(19):8934-46. PubMed ID: 27466420
[TBL] [Abstract][Full Text] [Related]
18. CD8
Kurachi M
Semin Immunopathol; 2019 May; 41(3):327-337. PubMed ID: 30989321
[TBL] [Abstract][Full Text] [Related]
19. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.
Gupta PK; Godec J; Wolski D; Adland E; Yates K; Pauken KE; Cosgrove C; Ledderose C; Junger WG; Robson SC; Wherry EJ; Alter G; Goulder PJ; Klenerman P; Sharpe AH; Lauer GM; Haining WN
PLoS Pathog; 2015 Oct; 11(10):e1005177. PubMed ID: 26485519
[TBL] [Abstract][Full Text] [Related]
20. Transcription Factor IRF4 Promotes CD8
Man K; Gabriel SS; Liao Y; Gloury R; Preston S; Henstridge DC; Pellegrini M; Zehn D; Berberich-Siebelt F; Febbraio MA; Shi W; Kallies A
Immunity; 2017 Dec; 47(6):1129-1141.e5. PubMed ID: 29246443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
